The HemOnc Pulse

Epizody

• 
  Rewriting the Treatment Playbook for MDS/MPN and Myelofibrosis 14.08.2026 21min

  In this Editor’s Special episode of The HemOnc Pulse, MD Anderson Cancer Center’s Naval Daver, MD, and Naveen Pemmaraju, MD, discuss MDS/MPN overlap conditions and research examining combination therapy with ruxolitinib and azacitidine (AZA), including its potential to improve disease response, symptom control, and outcomes.
• 
  Taking Bispecific Antibodies Outpatient: Lessons From the Front Lines 29.07.2026 12min

  As bispecific antibodies become a cornerstone of multiple myeloma treatment, safely transitioning patients to outpatient care is a growing priority.
• 
  Community-Based CAR-T Therapy: Expanding Access, Navigating Challenges 08.06.2026 11min

  Dr. Rahul Banerjee speaks with Dr. Gary Simmons about how community-based cellular therapy programs are expanding access to innovative cancer treatments.
• 
  Cutting GVHD Risk: What’s Changing in Allogeneic Transplants? 30.03.2026 16min

  Rahul Banerjee, MD speaks with Sagar S. Patel, MD of University of Utah Health about how new approaches in allogeneic transplants, from PTCy to innovative regimens, are helping reduce GVHD and improve patient outcomes.
• 
  MRD at the Regulatory Crossroads in Multiple Myeloma 06.02.2026 14min

  An Editor’s Special Episode featuring Nicholas Richardson, DO, MPH.
• 
  The Data Problem in T-Cell Lymphoma Care 27.01.2026 8min

  Dr. Francine Foss joins Dr. Rahul Banerjee, to discuss T-cell lymphomas, the need for real-world data, and how collaborative registries are advancing research and patient care.
• 
  XPO1 Inhibition Across the Myeloma Journey 26.12.2025 17min

  This Editor’s Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today’s evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlighting how selinexor can be used flexibly across multiple lines, including as a bridge to future immunotherapies. The conversation emphasizes individualized, dynamic treatment planning to balance disease control, tolerability, and long-term goals in an increasingly complex era of myeloma care.
• 
  Holding the Line in AML: Real-World Care Meets Breakthrough Trials 20.12.2025 9min

  Dr. Eunice Wang joins host Rahul Banerjee, MD, for a clinician-focused discussion on AML, treatment complexity, and real-world leukemia management in today’s evolving therapeutic landscape.
• 
  Under the Hood: Exploring the Genomic Engines of Smoldering Myeloma 17.10.2025 14min

  In this episode of The HemOnc Pulse, Dr. Omar Nadeem of Dana-Farber Cancer Institute discusses how genomic data are reshaping the understanding of smoldering myeloma. He explains why traditional risk models may fall short and how molecular insights could guide earlier, more precise intervention. “We’re really left with more disease-burden-based risk stratification tools,” Dr. Nadeem notes, “but not necessarily any of the genomic data that tell us what’s happening underneath the hood.”
• 
  Toxicity, Time, and the Patient Experience in Blood Cancers 03.10.2025 21min

  Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.
• 
  Editor's Special Episode: Future Directions in MPN Treatment with Dr. Hobbs 01.10.2025 17min

  Dr. Gaby Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.
• 
  Clinical Advances in Myeloma: A Nordic Perspective 12.09.2025 12min

  Rahul Banerjee, MD interviews Drs. Schjesvold and Askeland on new myeloma trial data, enrollment of elderly patients, and the importance of inclusive, investigator-driven research.
• 
  Grand Rounds in Leukemia: MD Anderson Fellows on AML Endpoints 07.09.2025 9min

  MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.
• 
  Editor’s Special Episode: Progress and Prospects in CLL Management 27.08.2025 23h 22min

  Listen to Dr. William Wierda discuss the modern management of CLL.
• 
  Today’s Clinical Trials Define the Next Era in Myeloma 22.08.2025 20h 31min

  Blood Cancers Today interviews Dr. Hira Mian during an Editor’s Special Episode.
• 
  ‘The HemOnc Pulse Live:’ Transforming ALL Treatment Pathways 15.08.2025 31h 22min

  Expert panel at The HemOnc Pulse Live event discuss the evolution of ALL treatment.
• 
  Evolving Approaches in the Management of MDS 08.08.2025 31min

  An Editor’s Special Episode featuring Andrew Brunner, MD
• 
  ‘The HemOnc Pulse Live!’: AML in Transition 01.08.2025 42h 11min

  Panel of experts led by Naval Daver, MD discusses mutation loss, minimal residual disease, and transplant timing in AML treatment.
• 
  From Trials to Practice: What's New and What's Next for Myeloma 25.07.2025 37min

  Drs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.
• 
  Editor’s Special Episode: Innovations in B-NHL 18.07.2025 22min

  This special episode explores major updates in B-cell non-Hodgkin lymphoma treatment from ASCO 2025, including advances in targeted therapies, evolving approaches to drug sequencing, and the impact of novel combinations across subtypes like CLL, follicular, mantle cell, and large B-cell lymphoma.